Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Senior VP, R&D | March 05, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date March 05, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,062 |
Reported balance
After 2026-03-05 transaction · row 1
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 5,284 · Balance 20,062 F1: Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.91 · Expires 2036-03-05 | Direct | 5,669 |
Reported balance
After 2026-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-05 · Grant · Acquired 5,669 · Balance 5,669 F2: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Jun 11, 2019 23:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 4,061 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016508 · doc4a.xml · derivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Underlying: Common Stock · 4,061 shares Expires 2029-02-28 F1 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:22 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 311 | $54.44 | $16,930.84 |
DisclosureSEC source: 0000899243-18-031479 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,294 F1 · shares: Sale of 311 shares in the open market valued at a price of $54.44 per share on December 18,2018 to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 03:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 12,850 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0001140361-18-012141 · doc1.xml · derivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,850 Underlying: Common Stock · 12,850 shares Expires 2028-03-01 F2 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 03:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 6,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-012141 · doc1.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 F1 · shares: Mr. Kuriyel was awarded 6,643 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.